Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Analysts have recently evaluated BioNTech and provided 12-month price targets. The average target is $134.42, accompanied by ...

NASDAQ tested new highs, supported by the strong performance of Apple stock. Shopify, which gained 21.2%, was the biggest ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Palantir stock surges in pre-market after crushing earnings estimates, boosting Nasdaq 100 and tech stock forecasts across US ...

Despite this dip, the stock is still up 25% over the last month—significantly outpacing the S&P 500’s modest 1.2% increase.

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is currently conducting a post-marketing surveillance study ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...